618 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,428 published Semaglutide COA source records from third-party laboratories, covering 609 publicly attributable vendor identities. Across 2,222 records with positive numeric purity, the arithmetic mean is 99.66%. 12 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 3 positive purity results are below 90%; 90 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-20, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $5.50 | $5.50–$5.50 | $1.10 | 1 source · 1 offer |
| 10 mg | $8.00 | $8.00–$8.00 | $0.80 | 1 source · 1 offer |
| 15 mg | $9.50 | $9.00–$10.00 | $0.63 | 2 sources · 2 offers |
| 20 mg | $11.83 | $10.50–$13.00 | $0.59 | 3 sources · 3 offers |
| 30 mg | $16.00 | $14.00–$18.00 | $0.53 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-20T01:22:29.581317+00:00. Calculation time is not a laboratory observation date.
Within that total, 482 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 45 | 99.8% | 0 of 40 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 34 | 99.48% | 0 of 30 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 29 | 99.43% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120870 (99.76%) · #120569 (99.95%) · #120845 (99.8%) · #120837 (99.85%) · #120830 (99.79%) · #120620 (99.57%)
Retatrutide, a GIP/GLP-1/glucagon receptor agonist, was assessed for its impact on kidney parameters in patients with type 2 diabetes mellitus (T2D) and kidney disease.
A new study is evaluating whether adding **semaglutide** to **dapagliflozin** improves outcomes for **heart failure** patients with prosthetic heart valves.
This review reinforces **semaglutide's** broad utility, extending beyond **T2DM** and **obesity** to include **MASLD**, offering a new therapeutic avenue for a complex liver condition. For peptide users and clinicians…
**Semaglutide offers a robust and effective therapeutic option for managing antipsychotic-induced weight gain**, a critical unmet need in psychiatric care. This meta-analysis provides strong evidence supporting its us…
This preclinical study suggests **semaglutide could emerge as a novel pharmacotherapy for Opioid Use Disorder (OUD)**, offering a new avenue for treatment beyond current options. The ability of semaglutide to reduce b…
This research presents a significant advancement for patients requiring long-term peptide therapies, particularly those for **Type 2 Diabetes** and **obesity**. **A single hydrogel injection could replace daily or wee…
This study provides crucial context for interpreting patient-reported outcomes in **obesity** research, highlighting that observational cohorts may represent a population with a higher baseline burden of disease and l…
Semaglutide 2.4 mg effectiveness and patient outcomes in adolescents with obesity are the focus of a real-world study addressing limited data in complex populations.
This real-world data suggests that **semaglutide can achieve substantial weight loss even at submaximal doses**, offering flexibility in treatment strategies for individuals with **obesity**. For peptide users and cli…
This economic evaluation provides crucial justification for the value of **phentermine-topiramate** and **semaglutide** in managing adolescent obesity, even at current pricing. For clinicians and policymakers, the fin…
This analysis from the `FLOW` trial reinforces that **semaglutide offers broad and consistent kidney and survival protection** for individuals with **Type 2 Diabetes** and **Chronic Kidney Disease**, regardless of the…
This validated semi-mechanistic PK model offers a powerful tool for optimizing future oral **semaglutide** formulations and understanding its behavior in diverse populations. **For peptide users and biohackers, this r…
**Understanding semaglutide's role in managing obesity in PWH could offer a crucial new therapeutic avenue**, potentially improving not only weight but also complex immune and metabolic health. If successful, this res…
A preliminary randomized controlled trial is investigating whether **semaglutide 0.25 mg** weekly improves intestinal barrier function in **SBS-IF** patients over 28 days.
Understanding the pharmacokinetic interactions of **insulin icodec** and **semaglutide** in a fixed-ratio combination like **IcoSema** is critical for advancing **Type 2 Diabetes** treatment. **This research provides …
This research provides compelling preclinical evidence that **semaglutide and other GLP-1R agonists may offer a direct pharmacological approach to improve lymphatic function**, potentially revolutionizing the treatmen…
This study suggests that **genotype-informed nursing strategies can personalize semaglutide treatment**, particularly for patients with `TCF7L2` CT/TT genotypes who might initially respond less favorably. By providing…
This large-scale, real-world evidence provides significant reassurance regarding the ocular safety profile of **semaglutide** concerning **neovascular age-related macular degeneration (NVAMD)**. Given previous concern…
This research offers a promising strategy to mitigate the undesirable **skeletal muscle loss** associated with GLP-1 RA therapies like semaglutide, a major concern for patients and clinicians. By combining semaglutide…
This study provides compelling preclinical evidence that **semaglutide could be a valuable non-opioid treatment for Opioid Use Disorder (OUD)**. Its once-weekly dosing schedule, compared to daily injections for other …
This research provides crucial pharmacokinetic and safety data, indicating that **cagrilintide** can be administered without dose adjustments in patients with mild, moderate, or severe renal or hepatic impairment. **T…
This study provides crucial economic evidence supporting the integration of **semaglutide for HFpEF with obesity** into healthcare systems, particularly in Germany. While semaglutide demonstrates cost-effectiveness ov…
The successful development and approval of a semaglutide biosimilar could significantly impact global healthcare by **improving access and affordability for GLP-1 receptor agonist therapies**. This would allow more in…
**Establishing the safety and tolerability of GLP-1 RAs in maintenance dialysis patients is a critical step towards expanding treatment options for a high-risk population.** Currently, these patients are largely exclu…
A prospective, non-interventional study in Sweden will assess oral semaglutide's impact on blood sugar levels in **Type 2 Diabetes** patients under routine clinical care.
**This case highlights a viable non-insulin strategy for advanced T2DM patients with cognitive impairment, offering a safer alternative to insulin.** For clinicians, it suggests that a carefully selected combination o…
Oral semaglutide **25 mg** and injectable semaglutide **2.4 mg** demonstrate comparable weight loss efficacy and safety profiles in adults with obesity, an indirect comparison confirms.
This indirect comparison provides crucial insights for clinicians and individuals managing **obesity** and **overweight**, offering a comparative view of two prominent oral GLP-1R agonists where head-to-head trials ar…
**Clinicians should be aware of potential associations between these drugs and nAMD risk**, especially when prescribing to patients with existing risk factors or early signs of macular degeneration. This study provide…
Semaglutide demonstrated robust therapeutic effects in individuals with Alcohol Use Disorder (AUD), supporting its potential as a novel treatment strategy.
Orforglipron significantly reduced **HbA1c** more than oral semaglutide in **type 2 diabetes** patients inadequately controlled with metformin over 52 weeks.
A multicenter observational study aims to compare **Semaglutide**'s weight loss efficacy (hypothesized **4.2 kg**) against other GLP-1 RAs (hypothesized **2.5 kg**) in **Type 2 Diabetes** patients.
The GAPSID study investigates how GLP-1 analogues mechanistically prevent steroid-induced hyperglycemia compared to metformin in pre-diabetic individuals.
Establishing the pharmacokinetic profile of oral semaglutide in patients with **renal impairment** is paramount for optimizing clinical outcomes and patient safety. If kidney dysfunction significantly alters drug expo…
Addressing a critical unmet need, this protocol targets **obese patients on atypical antipsychotics**, particularly those in secure care, where weight gain is severe and lifestyle interventions are challenging. If suc…
If the hypothesis proves true, this study could **redefine the therapeutic landscape for bone health in type 2 diabetes**, offering a novel strategy to mitigate fracture risk using an already established T2D medicatio…
A randomized crossover study will investigate the pharmacokinetics of **semaglutide** and **insulin 287** when administered alone or in combination in **Type 2 Diabetes** patients.
This study underscores that **integrating structured health behavior and lifestyle therapy (HBLT) is crucial for maximizing the effectiveness and adherence of GLP-1RAs like liraglutide in adolescents with obesity**. I…
**GLP-1RAs offer a mechanistically novel therapeutic option for Substance Use Disorders**, targeting central neural reward circuits beyond the scope of existing pharmacotherapies. This opens new avenues for adjunct or…
This case highlights a rare but significant ocular adverse event potentially associated with **semaglutide** dose escalation, urging heightened clinical vigilance. **Healthcare providers should consider atypical optic…
Oral semaglutide (Wegovy) 50 mg once daily showed therapeutic efficacy and a favorable safety profile for chronic weight management in adults with overweight or obesity across OASIS trials.
This review highlights a **critical evidence gap** regarding the direct effects of GLP-1 receptor agonists on thyroid function tests in humans. While large-scale data suggest no increased risk of thyroid malignancy, t…
This Phase II trial positions **BGM0504** as a promising new therapeutic option for **Type 2 Diabetes**, particularly within the Chinese population. The observed dose-dependent `HbA1c` reductions, reaching up to **-2.…
This study provides crucial evidence that a generic **semaglutide** injection is therapeutically equivalent to the innovator product, **Ozempic**, for managing **Type 2 Diabetes Mellitus**. **This finding significantl…
This Fc-binding conjugation strategy offers a broadly applicable method to extend the half-life of peptide therapeutics, potentially reducing injection frequency for patients with **Type 2 diabetes mellitus** and othe…
The introduction of disease-modifying therapies like **lecanemab** and **donanemab** represents a critical shift, emphasizing the importance of **early diagnosis** and comprehensive geriatric assessment to balance eff…
For individuals with **diabetes, cardiovascular disease, or cancer**, GLP-1RAs offer a dual benefit of substantial weight loss and reduced cardiovascular risk, reinforcing their role as a cornerstone therapy. While di…
This multicenter study provides compelling evidence that **GLP-1 RAs are a safe and moderately effective therapeutic option for managing post-liver transplant weight gain and improving metabolic health**. Given the hi…
This study provides critical real-world data underscoring the potential risks associated with **semaglutide exposure before and during pregnancy**. For individuals using `GLP-1R` agonists for weight management, these …
This survey underscores the growing need for **integrated aesthetic management** alongside **GLP-1 agonist** therapy. Clinicians and patients must be prepared for potential aesthetic side effects like facial fat loss …
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account